Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : S-969
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : National Institutes of Health
Deal Size : $1.9 million
Deal Type : Funding
Details : The funding will be used to conduct Investigational New Drug (IND) enabling studies for S-969, a first-in-class small molecule that may halt or reverse muscle wasting diseases, like muscular dystrophies, cachexia and sarcopenia.
Product Name : S-969
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 20, 2023
Lead Product(s) : S-969
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : National Institutes of Health
Deal Size : $1.9 million
Deal Type : Funding
Reset All
